Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2005.064857v1, 2006; 10.1373/clinchem.2005.064857
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.064857v1
52/5/832    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by James, S.
Right arrow Articles by Venge, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by James, S.
Right arrow Articles by Venge, P.

Received on December 5, 2005
Accepted on February 17, 2006

Proteomics and Protein Markers

The Antibody Configurations of Cardiac Troponin I Assays May Determine Their Clinical Performance

Stefan James 1, Mats Flodin 2, Nina Johnston 3, Bertil Lindahl 1, Per Venge 2*

1 Department of Medical Sciences, Cardiology, Uppsala Clinical Research Centre, Uppsala, Sweden
2 Clinical Chemistry, Uppsala University, Uppsala, Sweden
3 Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

* To whom correspondence should be addressed. E-mail: per.venge{at}akademiska.se.

Background: Previous studies have shown superior clinical performance of the cardiac troponin I (cTnI) assay from Beckman-Coulter Diagnostics. This assay had a unique combination of monoclonal antibodies with 2 monoclonal antibodies directed against epitopes near the NH2 terminus of the heart-specific region of troponin I. The approach has been adopted by the new cTnI assay from Abbott Diagnostics. The aim of our study was to investigate whether this approach affects the clinical performance of cTnI assays.

Methods: Cardiac troponin concentrations were measured in a random sample of patients with unstable coronary artery disease included in the GUSTO IV trial (n = 696) by the AccuTnI (Beckman-Coulter Diagnostics), Architect cTnI (Abbott Diagnostics), Immulite 2500 cTnI (Diagnostics Products Corporation), and Elecsys 2010 cTnT (Roche Diagnostics) assays and related to the 1-year mortality. The primary cutoff concentrations were based on the 99th percentile upper reference limits and an imprecision (CV) ≤10%.

Results: The sensitivities of the AccuTnI and Architect cTnI assays in identifying patients who died within 1 year were equal and were significantly higher (P <0.05) than those of the Immulite 2500 cTnI and the Elecsys cTnT assays. The concordance between the AccuTnI and Architect cTnI assays was 97%, but concordances between the Architect cTnI and the Elecsys cTnT assays were 89%-92% with more at-risk patients (P <0.01 to P <0.001) identified by the Architect cTnI assay.

Conclusions: The Architect cTnI assay has clinical performance similar to that of the AccuTnI, probably as a result of the inclusion of a monoclonal antibody against troponin I epitope 41-49 in the assay.




The following articles in journals at HighWire Press have cited this article:


Home page
Ann Clin BiochemHome page
J. R Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, and A. Carter
The determination of the 99th centile level for troponin assays in an Australian reference population
Ann Clin Biochem, May 1, 2008; 45(3): 275 - 288.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E.F. Melanson, M. J. Tanasijevic, and P. Jarolim
Cardiac Troponin Assays: A View From the Clinical Chemistry Laboratory
Circulation, October 30, 2007; 116(18): e501 - e504.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
P. A. Kavsak, A. M. Newman, V. Lustig, A. R. MacRae, G. E. Palomaki, D. T. Ko, J. V. Tu, and A. S. Jaffe
Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations
Clin. Chem., February 1, 2007; 53(2): 220 - 227.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.